1. Introduction {#sec1}
===============

Mucosa-associated lymphoid tissue (MALT) lymphomas are extranodal B cell lymphomas and a type of marginal zone lymphoma. The most common sites of MALT lymphomas are the stomach, spleen, and the eye/adnexa. MALT lymphomas of the breast are exceedingly rare. It has been hypothesized that the rarity of primary breast lymphomas, which account for just 0.4--0.5% of all breast malignancies and 1.7--2.2% of all extranodal lymphomas, is due to the scarcity of mucosa-associated lymphoid tissue in the breast \[[@B1], [@B2]\]. We report a case of primary breast MALT and we review the currently available literature on etiology, pathogenesis, diagnosis, prognosis, and treatment of this rare manifestation of a MALT.

2. Case Report {#sec2}
==============

The patient has been undergoing routine screening mammograms since the age of 40. On her annual screening mammogram, a 9 mm left breast mass was noted. She underwent a stereotactic core biopsy, which demonstrated an expansion of B cells found in irregularly shaped aggregates, which were associated with disrupted follicular dendritic cell meshworks. The B cells were CD20 positive, but negative for CD5, CD10, and BCL6; these findings were consistent with MALT of the breast ([Figure 1](#fig1){ref-type="fig"}).

The patient underwent staging workup, which included positron emission tomography (PET) imaging, computerized topography (CT) imaging, and a bone marrow biopsy. The PET scan showed mild uptake in an 8 mm left breast nodule ([Figure 2(a)](#fig2){ref-type="fig"}). Bone marrow biopsy was negative. The patient denied any B-symptoms and was staged as IAE MALT lymphoma of the breast.

Treatment options were discussed, including lumpectomy and definitive radiation therapy. The patient elected definitive radiation therapy. The patient received definitive 3D conformational radiation therapy treatment to a total dose of 3000 cGy in 15 fractions ([Figure 3](#fig3){ref-type="fig"}). The treatment included the PET positive area with a small margin; the patient experienced no toxicity, including dermatitis, due to the minimally involved treatment area. At her three-month follow-up, she had no evidence of disease ([Figure 2(b)](#fig2){ref-type="fig"}).

3. Discussion {#sec3}
=============

Non-Hodgkin lymphomas (NHL) are malignancies that originate in lymphoid tissue and arise from T cells, B cells, and natural killer (NK) cells, with MALTs representing only 5% of all NHL \[[@B3]\]. The etiology of NHL is poorly understood; however, the most significant risk factor for development of all NHL is immunodeficiency \[[@B4]\]. Interestingly, MALT lymphomas specifically have been associated with robust, prolonged inflammation in the case of*Helicobacter pylori* infection and with chronic immune system dysregulation in the case of Sjögren\'s syndrome and Hashimoto\'s thyroiditis \[[@B5]--[@B8]\].

The precise mechanism of the pathogenesis of breast MALT is not known; however, there is a hypothesis that sex hormones modulate immune function and the development of NHL. Nevertheless, findings concerning the specific role of estrogen in the development of NHL as a whole are mixed; some studies have found no effect, while others have found a protective or contributory effect \[[@B9]--[@B11]\]. Further research on the proliferative effects of estrogen in malignant conditions could be beneficial in the development of new treatments; there is some current evidence to support the proposition that estrogen receptor *β* may modulate the proliferative effects of estrogen receptor *α* \[[@B12]\]. Further research on the balance between proliferative (ER*α*) and antiproliferative (ER*β*) effects of estrogen receptors could lead to new NHL cancer treatments.

Patients with breast MALT may present with a unilateral palpable mass; however, most patients will be otherwise asymptomatic, including absence of classic B-symptoms \[[@B13], [@B14]\]. In a retrospective study of lymphomatous disease of the breast, the overwhelming majority of patients detected their disease by palpation of a breast mass rather than mammography \[[@B15]\]. Routine mammography may be useful in detecting MALTs. Once a diagnosis of MALT is established, the standard lymphoma workup including bone marrow analysis should be performed.

The prognosis of patients affected by breast MALT will depend, in part, on their clinical stage. Additional predictive factors include age, number of extranodal sites, performance status, and LDH levels. The treatment for primary breast lymphoma is not yet fully established. However, for localized MALT lymphomas, radiation therapy alone can be used as the definitive treatment. For localized breast MALT, local radiation therapy, such as involved field radiation therapy, and a moderate dose of 25--30 Gy are recommended \[[@B16], [@B17]\]. Treatment guidelines by the International Lymphoma Radiation Oncology Group report a recommendation for whole breast radiation therapy, noting that partial breast radiation can be considered in some cases; in our case, we opted for partial breast radiation given the small tumor size in relation to her breast \[[@B18]\]. Local radiation therapy can yield control rates and overall-survival rates over 90% \[[@B13]\]. For our patient, we used involved site radiation therapy to a total dose of 30 Gy with excellent results; the patient had no evidence of disease at her 3-month follow-up.

For patients with disseminated disease, treatment options may include a watch-and-wait approach, biological therapy, and/or chemotherapy. Since tumors are generally highly receptive to radiation therapy and chemotherapy, mastectomy need not be considered and wide excision is not necessary in the majority of cases \[[@B13]\]. [Table 1](#tab1){ref-type="table"} summarizes treatment management for all reported cases of breast MALT lymphoma to date. Of 32 patients, 5 were treated with definitive radiation therapy, 1 patient received palliative radiation therapy, 1 patient received no treatment, 6 patients received chemotherapy alone, and 19 patients received surgery (either surgery alone or surgery in addition to chemotherapy, radiation therapy, or both). Of those that received definitive RT therapy, none died from progressive disease. Of the 6 patients who received chemotherapy alone, 1 died of progressive disease. Of the 19 patients who received surgery, 2 died of progressive disease. These findings further support the recommendation for definitive radiation therapy as a reasonable treatment option for breast MALT.

For MALT lymphomas treated with radiation therapy as the sole treatment modality, relapse rarely occurs distantly \[[@B19]\]. If the patient\'s cancer was detected by mammography, they should continue to undergo annual screening. They should also be counseled on secondary malignancy and risk of coronary artery disease depending on the dose to the heart.

In summary, breast MALTs are generally an indolent disease with an asymptomatic presentation, including absence of B-symptoms. For localized disease, definitive radiation represents a reasonable treatment option with excellent response, local control, and minimal toxicity.
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![Low and high power images of H&E stain show infiltration of the breast tissue by lymphocytes of MALT lymphoma. These lymphocytes have abundant pale cytoplasm leading to monocytoid features.](CRIHEM2016-1831792.001){#fig1}

![Pretreatment axial PET showing left breast mass with avidity in the left breast (a) and posttreatment axial PET showing complete response with no avidity present in the left breast (b).](CRIHEM2016-1831792.002){#fig2}

![3D conformation radiation therapy planning of MALT breast lymphoma. Dose distribution in the axial (a), sagittal (b), and (c) coronal planes. The red area indicates the planning target volume (PTV) and the yellow line indicates the 30 Gy isodose line.](CRIHEM2016-1831792.003){#fig3}

###### 

Characteristics of breast MALT lymphoma cases available in the English language with a minimum follow-up of 3 months and a reported disease status outcome.

  Study                                   Age     Treatment                                                                                                                                      RT dose                              Disease status                   Follow-up (months)
  --------------------------------------- ------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ -------------------------------- --------------------
  Gupta et al., 2000 \[[@B20]\]           64      RT                                                                                                                                             44.2 Gy + R side boost up to 51 Gy   NED                              64
  Batstone et al., 2003 \[[@B21]\]        87      Palliative RT                                                                                                                                  (---)                                Alive with disease               11
  Ghetu et al., 2011 \[[@B22]\]           77      Lumpectomy; whole breast irradiation following breast relapse; rituximab following breast relapse; local RT following lacrimal gland relapse   (---)                                NED                              60
  Tsang et al., 2001 \[[@B23]\]           74      RT for primary breast MALT and resection for Ca ampulla of Vater relapse                                                                       (---)                                NED                              55
  Wright et al., 1996 \[[@B24]\]          55      RT                                                                                                                                             (---)                                NED                              168
  Zobolas et al., 2002 \[[@B25]\]         68      Breast conservation surgery; bilateral axillary lymph node dissection; 6 cycles of CHOP and RT (RT given 6 months after surgery)               (---)                                NED                              10
  Bailey et al., 1996 \[[@B26]\]          36      Excision, chemotherapy, and RT                                                                                                                 (---)                                NED                              46
  Rajendran et al., 2008 \[[@B27]\]       66      RT                                                                                                                                             4140 cGy in 23 fractions             NED                              72
  Matsuda et al., 2014 \[[@B28]\]         47      Mastectomy with sentinel node biopsy and radical axillary node dissection                                                                                                           NED                              6
  Arslan et al., 2012 \[[@B29]\]          69      CHOP protocol-8 cycles                                                                                                                                                              NED                              6
  Michael et al., 2005 \[[@B30]\]         59      2 cycles of chlorambucil + CHOP                                                                                                                                                     NED                              24
  Nassif and Ozdemirli, 2013 \[[@B31]\]   18      Excision                                                                                                                                                                            Alive with disease               4
  Huber et al., 2002 \[[@B32]\]           32      8 cycles of cyclophosphamide, Oncovin, and prednisolone                                                                                                                             NED                              48
  Julen et al., 2009 \[[@B33]\]           86      Patey surgery                                                                                                                                                                       NED                              60
  Kambouchner et al., 2003 \[[@B34]\]     37      No treatment                                                                                                                                                                        NED                              42
  Kim et al., 2015 \[[@B35]\]             55      Surgery                                                                                                                                                                             NED                              9
  Kuper-Hommel et al., 1999 \[[@B36]\]    65      3 cycles of CHOP                                                                                                                                                                    NED                              10
  Mattia et al., 1993 \[[@B37]\]          69      Excision                                                                                                                                                                            NED                              9
  Mattia et al., 1993 \[[@B37]\]          77      Excision                                                                                                                                                                            NED                              48
  Mattia et al., 1993 \[[@B37]\]          81      Excision                                                                                                                                                                            NED                              10
  Mattia et al., 1993 \[[@B37]\]          65      Excision                                                                                                                                                                            Death from progressive disease   25
  Raderer et al., 2005 \[[@B38]\]         59      4 cycles of oxaliplatin                                                                                                                                                             NED                              20
  Said et al., 2013 \[[@B39]\]            52      Cyclophosphamide, steroid, and CHOP                                                                                                                                                 Death from progressive disease   12
  Taeda et al., 2006 \[[@B40]\]           84      Mastectomy with axillary lymph node dissection and 4 cycles of rituximab                                                                                                            NED                              18
  Welsh et al., 2006 \[[@B41]\]           66      Lumpectomy and 30.6 Gy in 18 fractions                                                                                                                                              NED                              36
  Anavekar et al., 2008 \[[@B42]\]        56      Surgery, postoperative RT, and tamoxifen                                                                                                                                            NED                              24
  Kuper-Hommel et al., 2003 \[[@B43]\]    (---)   RT                                                                                                                                             (---)                                Death from unrelated causes      59
  Kuper-Hommel et al., 2003 \[[@B43]\]    (---)   Surgery                                                                                                                                                                             NED                              134
  Kuper-Hommel et al., 2003 \[[@B43]\]    (---)   Surgery and anthracycline-containing chemotherapy regimen                                                                                                                           NED                              74
  Kuper-Hommel et al., 2003 \[[@B43]\]    (---)   Surgery and chemotherapy                                                                                                                                                            NED                              66
  Kuper-Hommel et al., 2003 \[[@B43]\]    (---)   Surgery                                                                                                                                                                             NED                              16
  Kuper-Hommel et al., 2003 \[[@B43]\]    (---)   Surgery and anthracycline-containing chemotherapy regimen                                                                                                                           Death from progressive disease   107

SOB: shortness of breath.

CXR: chest X-ray.

NED: no evidence of disease.
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